Literature DB >> 22197410

Transcatheter aortic valve implantation: assessing the learning curve.

Oluseun O Alli1, Jeffrey D Booker, Ryan J Lennon, Kevin L Greason, Charanjit S Rihal, David R Holmes.   

Abstract

OBJECTIVES: The aim of this study was to assess the learning curve for the implantation of the percutaneous aortic valve via the transfemoral route.
BACKGROUND: Transcutaneous aortic valve insertion is a fundamentally new procedure for the treatment of aortic valve stenosis. The number of cases needed to gain proficiency with concomitant ease and familiarity (i.e., the "learning curve") with the procedure is unknown.
METHODS: We performed a retrospective analysis of the first 44 consecutive patients who underwent transcatheter aortic valve implantation as part of the PARTNER (Placement of Aortic Transcatheter Valves) trial at our institution between November 2008 and May 2011.
RESULTS: The median age of the patients was 83 years (interquartile range: 77 to 87 years) and a median Society of Thoracic Surgery risk score of 9.6. Pre-procedural assessment of the aortic valve revealed a mean gradient of 53.5 mm Hg, mean aortic valve area of 0.7 mm(2), and a median ejection fraction of 59.5%. Patients were divided into tertiles based on sequence. Significant decreases in median contrast volume (180 to 160 to 130 ml, p = 0.003), valvuloplasty to valve deployment time (12.0 to 11.6 to 7.0 min, p < 0.001) and fluoroscopy times, from 26.1 to 17.2 and 14.3 min occurred from tertiles 1 to 3, p < 0.001. Significant decreases in radiation doses were also seen across the 3 tertiles, p < 0.001. The 30-day mortality for the entire cohort was 11%.
CONCLUSIONS: Experience accumulated over 44 transfemoral aortic valve implantations led to significant decreases in procedural times, radiation, and contrast volumes. Our data show increasing proficiency with evidence of plateau after the first 30 cases. More studies are needed to confirm these findings.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22197410     DOI: 10.1016/j.jcin.2011.09.014

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  21 in total

1.  Is proctoring mandatory when starting a TAVI program?

Authors:  Mattia Glauber; Michele Murzi; Alfredo G Cerillo
Journal:  Ann Cardiothorac Surg       Date:  2012-07

2.  Introduction to transcatheter aortic valve implantation.

Authors:  Neal Kleiman
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Apr-Jun

3.  Room considerations with TAVR.

Authors:  Neal Kleiman
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Apr-Jun

Review 4.  TAVI 2012: state of the art.

Authors:  Jochen Reinöhl; Constantin von Zur Mühlen; Martin Moser; Stefan Sorg; Christoph Bode; Manfred Zehender
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

5.  Volume, outcome, and policy.

Authors:  Mark A Hlatky
Journal:  J Interv Card Electrophysiol       Date:  2012-12-18       Impact factor: 1.900

6.  A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis.

Authors:  Albert Markus Kasel; Salvatore Cassese; Thomas Ischinger; Alexander Leber; Diethmar Antoni; Gotthard Riess; Jayshree Vogel; Adnan Kastrati; Walter Eichinger; Ellen Hoffmann
Journal:  Am J Cardiovasc Dis       Date:  2014-06-28

Review 7.  Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: an updated review of literature.

Authors:  Saurav Chatterjee; Dharam Jaydeep Kumbhani; Partha Sardar; Anasua Chakraborty; Giuseppe Biondi-Zoccai; Manpreet Singh Sabharwal; Richard Ro; Balaji Pratap; Chirag P Bavishi; Sripal Bangalore
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

8.  Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement.

Authors:  Sahil Khera; Dhaval Kolte; Tanush Gupta; Andrew Goldsweig; Poonam Velagapudi; Ankur Kalra; Gilbert H L Tang; Wilbert S Aronow; Gregg C Fonarow; Deepak L Bhatt; Herbert D Aronow; Neal S Kleiman; Michael Reardon; Paul C Gordon; Barry Sharaf; J Dawn Abbott
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

9.  Temporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement: A Placement of AoRTic TraNscathetER Valve (PARTNER) Trial Substudy.

Authors:  Hemal Gada; Ajay J Kirtane; Kaijun Wang; Yang Lei; Elizabeth Magnuson; Matthew R Reynolds; Mathew R Williams; Susheel Kodali; Torsten P Vahl; Suzanne V Arnold; Martin B Leon; Vinod Thourani; Wilson Y Szeto; David J Cohen
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-09

10.  Learning curves for transapical transcatheter aortic valve replacement in the PARTNER-I trial: Technical performance, success, and safety.

Authors:  Rakesh M Suri; Sa'ar Minha; Oluseun Alli; Ron Waksman; Charanjit S Rihal; Lowell P Satler; Kevin L Greason; Rebecca Torguson; Augusto D Pichard; Michael Mack; Lars G Svensson; Jeevanantham Rajeswaran; Ashley M Lowry; John Ehrlinger; Stephanie L Mick; E Murat Tuzcu; Vinod H Thourani; Raj Makkar; David Holmes; Martin B Leon; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2016-04-13       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.